USPTO Art Unit 1699 Prosecution Statistics

Art Unit Information

Art Unit: 1699
Group: 1690
Tech Center: 1600
Total Cases: 4,266
Last Active: February 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19046435COMPOSITIONS AND METHODS FOR MINIMUM RISK PEST CONTROLFebruary 2025April 2025Allow200YesNo
19017364ANTI-MICROBIAL TREATMENT FOR SEEDS AND CROPSJanuary 2025April 2025Allow300YesNo
18870764COSMETIC COMPOSITIONDecember 2024April 2025Allow400NoNo
18783039NANO PESTICIDAL FORMULATION AND PREPARATION METHOD THEREOFJuly 2024March 2025Allow820NoNo
18775678POLYSILANE METHACRYLIC COMPOUNDS AND METHODS OF MAKING THEMJuly 2024September 2024Allow200NoNo
18775693POLYSILANE METHACRYLIC COMPOUNDS AND METHODS OF MAKING THEMJuly 2024September 2024Allow200NoNo
18760458DUAL MODULATOR OF MGLUR5 AND 5-HT2A RECEPTOR, AND USE THEREOFJuly 2024June 2025Allow1110NoNo
18665923FUSED RING DERIVATIVE HAVING MGAT-2 INHIBITORY ACTIVITYMay 2024June 2025Allow1311YesNo
18662947INHIBITORS OF BUNYAVIRIDAE AND USES THEREOFMay 2024March 2025Allow1010YesNo
18662301Preparation method and application of water-soluble chlorhexidine hyaluronate antibacterial agentsMay 2024December 2024Allow720YesNo
18659052SUBSTITUTED NITROGEN CONTAINING COMPOUNDSMay 2024June 2025Abandon1310NoNo
18653713PHARMACEUTICAL COMPOSITIONMay 2024July 2025Allow1431YesNo
18640607THERAPEUTICALLY ACTIVE STEROIDAL DERIVATIVESApril 2024May 2025Abandon1310NoNo
18634556POLYSILANE METHACRYLIC COMPOUNDS AND METHODS OF MAKING THEMApril 2024July 2024Allow401NoNo
18625676Animal Feeds and Feed Premixes Containing Betaine Hydrochloride and a PhytaseApril 2024April 2025Allow1210NoNo
18625655CATIONIC POLYMERSApril 2024March 2025Allow1200NoNo
18606927CLINICAL FORMULATIONSMarch 2024May 2025Allow1420NoNo
18600631ADDITIVE INGREDIENTS OF SYNERGISTS AND SURFACTANTS PROVIDED IN A SINGLE-USE TRANSPORTER PREFERABLY FOR USE WITH WEED CONTROL, INSECT CONTROL AND MOLD REMOVAL COMPOSITIONSMarch 2024August 2024Allow501YesNo
18587730CARDIAC SARCOMERE INHIBITORSFebruary 2024October 2024Allow700NoNo
18587753NOVEL SMALL MOLECULE COMPOUNDFebruary 2024April 2025Allow1310NoNo
18584709METHOD OF DETECTING SALMONELLA TYPHIMURIUMFebruary 2024March 2025Allow1210YesNo
18435744COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITYFebruary 2024April 2025Abandon1501NoNo
18681524METHOD FOR THE DIAGNOSIS AND/OR PROGNOSIS OF CANCER OF THE BILIARY TRACTFebruary 2024November 2024Allow911YesNo
18433950ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17February 2024February 2025Allow1310NoNo
18433029Methods and Compositions for Determining pHFebruary 2024June 2025Abandon1611NoNo
18429524METHODS OF TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERSFebruary 2024February 2025Abandon1301NoNo
18424597CELL POPULATIONS OF CD31-POSITIVE, CD45-NEGATIVE, CD200-POSITIVE MAMMALIAN CELLS AND USE THEREOFJanuary 2024February 2025Allow1200NoNo
18417535SUSTAINABLE NANOPARTICLE FORMULATION FOR MANAGEMENT OF RED PALM WEEVILJanuary 2024April 2024Allow300YesNo
18413175PROCESSES FOR PREPARING AG-10, ITS INTERMEDIATES, AND SALTS THEREOFJanuary 2024August 2024Allow700NoNo
18412907SE33 MUTATIONS IMPACTING GENOTYPE CONCORDANCEJanuary 2024March 2025Abandon1410NoNo
18409042CARRIER-FREE CURCUMIN NANOPARTICLES FOR EGFR-POSITIVE CANCER THERAPYJanuary 2024June 2025Allow1701NoNo
18404478N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-c]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODSJanuary 2024April 2025Allow1620YesNo
18390083APPARATUS AND METHODS USING TETHERED ENZYMES FOR THE DETECTION OF THE ENZYMATIC ACTIVITY OF BIOMARKERSDecember 2023March 2025Allow1521YesNo
18545335CELL CULTURE MEDIA COMPOSITIONS FOR PRIMARY CELLSDecember 2023March 2025Allow1511NoNo
18538176Boronated Multifunctional Targeting Drug Conjugates, Their Uses and Methods for Their PreparationDecember 2023March 2025Abandon1501NoNo
18524807AZABICYCLO AND DIAZEPINE DERIVATIVESNovember 2023October 2024Allow1110NoNo
18521400HETEROARYL CARBOXAMIDE COMPOUNDNovember 2023April 2024Allow511NoNo
18516940GRANULE FOR DETECTING GLUCOSE IN PET URINE AND METHOD FOR PREPARING THE SAMENovember 2023May 2024Allow610NoNo
18510936AMINATED PSILOCYBIN DERIVATIVES AND METHODS OF USINGNovember 2023March 2025Allow1631YesNo
18508838COMPOSITION FOR AMELIORATING OR TREATING DEMENTIA CONTAINING 2'-FUCOSYLLACTOSENovember 2023January 2025Allow1420NoNo
18507595DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND USES THEREOFNovember 2023April 2024Allow510YesNo
18507409METHOD FOR SELECTIVE RECOVERY OF LIPOPHILIC COMPOUNDSNovember 2023October 2024Abandon1110NoNo
18506179POLYPEPTIDES HAVING LYZOZYME ACTIVITY, POLUNUCLEOTIDES ENCODING SAME AND USES AND COMPOSITIONS THEREOFNovember 2023June 2025Allow1911NoNo
18388728{5-CHLORO-2-(2-(3-(SUBSTITUTEDPHENYL)-1,2,4-OXADIAZOL-5-YL)ETHYL)PHENYL}(PHENYL)METHANONES AS LARVICIDAL AGENTSNovember 2023March 2024Allow410NoNo
18505713CRYSTALLINE IMIDAZO[4,5-b]PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONSNovember 2023January 2025Allow1410YesNo
183865613-(4-NITROPHENYL)-5-((2-ISOPROPYL-5-METHYLPHENOXY)METHYL)-1,2,4-OXADIAZOLE AS AN ANTI-CANCER AND ANTIMICROBIAL COMPOUNDNovember 2023February 2024Allow300NoNo
18385345Fragrant Horticultural Care CompositionOctober 2023December 2024Allow1310YesNo
18493935GENES AND GENE SIGNATURES FOR DIAGNOSIS AND TREATMENT OF MELANOMAOctober 2023March 2025Allow1710YesNo
183829724,5-BIS(4-CHLOROPHENYL)-2-PHENYL-1H-IMIDAZOL-1-YL AS AN ANTIMICROBIAL COMPOUNDOctober 2023March 2024Allow510NoNo
183828191-(2-CHLOROBENZYLIDENEAMINO)-5,5-DIPHENYLIMIDAZOLIDINE-2,4-DIONE AS AN ANTIMICROBIAL COMPOUNDOctober 2023January 2024Allow310NoNo
18491523HETEROCYCLIC COMPOUNDS AS PESTICIDESOctober 2023April 2025Abandon1801NoNo
18484734N'-(2-(5-(4-CHLOROPHENYL)-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)-4-METHOXYBENZIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDOctober 2023December 2023Allow200YesNo
18484397N-[(2-{[(FURAN-YLCARBONYL)CARBAMOTHIOYL]AMINO}PHENYL)CARBAMOTHIOYL]FURAN-2-CARBOXAMIDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)October 2023March 2024Allow510YesNo
18374108COT MODULATORS AND METHODS OF USE THEREOFSeptember 2023April 2025Allow1911NoNo
18472571PLANT DISEASE CONTROL COMPOSITION AND METHOD FOR CONTROLLING PLANT DISEASE BY APPLYING THE SAMESeptember 2023March 2025Allow1711NoNo
18472147HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USESeptember 2023April 2025Allow1920NoNo
18470720TREATMENT OF CONNECTIVE TISSUE INJURIESSeptember 2023June 2024Allow910YesNo
18469518METHOD FOR PREPARING LIQUID MALTITOL AND LIQUID POLYOLS FROM A RAFFINATE INCLUDING MALTITOLSeptember 2023February 2024Allow500YesNo
18368189SELF-REGULATING OSMOTIC GASTRORETENTIVE DRUG DELIVERY SYSTEMSSeptember 2023August 2024Allow1110NoNo
18466804COMPOSITIONS AND DEVICES OF POLY-4-HYDROXYBUTYRATESeptember 2023May 2025Abandon2101NoNo
18464583TREATMENT OF STRESS DISORDERS USING ACETYLCHOLINE RELEASE INHIBITING NEUROTOXIC PROTEINS TO REDUCE STRESS LEVELSSeptember 2023August 2024Allow1110NoNo
18460337HEPATITIS B CORE PROTEIN MODULATORSSeptember 2023December 2024Abandon1610NoNo
18241009Bifidobacterium longum subsp. infantis with fimbriae and applications thereofAugust 2023June 2024Allow920YesNo
18446057METHOD FOR INCREASING FERROUS ION CONTENT IN BACILLUS COAGULANS AND COMPOUND MICROBIAL AGENTAugust 2023August 2024Abandon1220NoNo
18364080PRODUCING METHOD OF STRESS RELIEVERAugust 2023December 2024Allow1610YesNo
18361837RILUZOLE PRODRUGS AND THEIR USEJuly 2023March 2024Allow710NoNo
18222492MONOMERIC POLYSACCHARIDE ISOLATED FROM AURICULARIA AURICULA-JUDAE, AND PREPARATION METHOD AND USE THEREOFJuly 2023July 2024Allow1211YesNo
182179149-OXO-9,10-DIHYDRO-6H-PYRANO[3,2-B:4,5-B']DIPYRIDINE-8-CARBOXYLIC ACID DERIVATIVESJuly 2023December 2023Allow501YesNo
18270344CANCER TREATMENT REGIMEN USING ANTI-PARASITIC COMPOUNDS AND GUT MICROBIOME MODULATING AGENTSJune 2023September 2024Allow1511YesNo
18215475Method for Inducing Lateral Branch Development of Eucheuma DenticulatumJune 2023July 2024Abandon1320NoNo
18343554LYMPH DIRECTING PRODRUGSJune 2023February 2025Abandon2021NoNo
18214906MODULATION OF PLANT BIOLOGYJune 2023September 2024Allow1401YesNo
18335889REGULATE GUT MICROBIOTA TO TREAT NEURODEGENERATIVE DISORDERSJune 2023February 2025Allow2020NoNo
18333957MICROBIOLOGICAL GROWTH MEDIA AND METHODS OF USING THE SAMEJune 2023March 2025Allow2110NoNo
18333231BIOMARKERS FOR BIPOLAR DISORDER AND SCHIZOPHRENIAJune 2023April 2025Allow2320NoNo
18322474Methods of Administering 3,4-DiaminopridineMay 2023October 2023Allow510NoNo
18322342Methods of Administering 3,4-DiaminopridineMay 2023October 2023Allow510NoNo
18321092Triazole N-Linked Carbamoyl Cyclohexyl Acids as LPA AntagonistsMay 2023August 2024Allow1410NoNo
18199205SOLABEGRON ZWITTERION AND USES THEREOFMay 2023June 2025Allow2510NoNo
18198447HERBICIDAL MIXTURES COMPRISING L-GLUFOSINATE OR ITS SALT AND AT LEAST ONE PROTOPORPHYRINOGEN-IX OXIDASE INHIBITORMay 2023November 2024Allow1820YesNo
18198449HERBICIDAL MIXTURES COMPRISING L-GLUFOSINATE OR ITS SALT AND AT LEAST ONE PROTOPORPHYRINOGEN-IX OXIDASE INHIBITORMay 2023November 2024Allow1820YesNo
18196106INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR PROMOTING NEUROGENESIS AND INHIBITING NERVE CELL DEATHMay 2023April 2025Allow2400NoNo
18144247BLACK SOLDIER FLY (HERMETIA ILLUCENS) LARVAE FRASS FORMULATIONS, COMBINATIONS AND USESMay 2023March 2024Allow1101YesNo
18143529GENERATION OF METHANE FROM DIGESTION OF MARINE BROWN ALGAEMay 2023October 2023Allow610YesNo
18142802DECELLULARIZED BIOMATERIAL FROM NON-MAMMALIAN TISSUEMay 2023March 2025Allow2220NoNo
18032246BIOLOGICAL WATER RETENTION MATERIAL, METHOD FOR PREPARING SAME AND USE THEREOFApril 2023February 2025Allow2220YesNo
18031880METHOD FOR IMPROVING EFFICIENCY OF ANAEROBIC FERMENTATION IN MEDIUM TEMPERATURE-HIGH TEMPERATURE TRANSITION ZONEApril 2023June 2024Allow1420YesNo
18132743INHALABLE RAPAMYCIN FORMULATION FOR TREATING AGE-RELATED CONDITIONSApril 2023March 2025Abandon2320NoNo
18030231TARGETED PH SENSITIVE LIPOSOMESApril 2023May 2025Allow2600NoNo
18029941ANTIVIRAL COMPOSITION COMPRISING MODIFIED ZEOLITESApril 2023May 2024Allow1310YesNo
18192922Methods for the Epigenetic Analysis of DNA, Particularly Cell-Free DNAMarch 2023February 2025Abandon2311NoNo
18029582Bacterial Superoxide DismutasesMarch 2023May 2025Allow2601NoNo
18192382TRANSPOSITION-BASED THERAPIESMarch 2023April 2024Allow1210YesNo
18191445INTRAVENOUS GANAXOLONE FORMULATIONS AND METHODS OF USE IN TREATING STATUS EPILEPTICUS AND OTHER SEIZURE DISORDERSMarch 2023January 2025Abandon2130YesNo
18027897METHODS, PROCESSES, AND COMPOSITIONS FOR IMPROVED PREPARATION OF HU308 AND HU433March 2023February 2024Allow1110YesNo
18186257METHODS FOR FERMENTATIVE PRODUCTION OF MASSOIA LACTONEMarch 2023June 2024Allow1500NoNo
18183170COMPOUND MYCORRHIZAL FUNGUS GROWTH PROMOTING AGENT AND AGRICULTURAL-PHOTOVOLTAIC COMPLEMENTARY PLANTING METHOD FOR DIOSCOREA COMPOSITAMarch 2023March 2024Allow1220YesNo
181810466-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETESMarch 2023July 2024Abandon1710NoNo
18117852Methods for the Prevention and Treatment of Hearing LossMarch 2023August 2023Allow500YesNo
18179188CATALYTIC PROCESSES AND SYSTEMS FOR ALKYL SULFIDE PURIFICATIONMarch 2023December 2023Allow920NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1699.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
53
Examiner Affirmed
38
(71.7%)
Examiner Reversed
15
(28.3%)
Reversal Percentile
28.7%
Lower than average

What This Means

With a 28.3% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
264
Allowed After Appeal Filing
71
(26.9%)
Not Allowed After Appeal Filing
193
(73.1%)
Filing Benefit Percentile
19.9%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 26.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1699 - Prosecution Statistics Summary

Executive Summary

Art Unit 1699 is part of Group 1690 in Technology Center 1600. This art unit has examined 4,266 patent applications in our dataset, with an overall allowance rate of 75.2%. Applications typically reach final disposition in approximately 30 months.

Comparative Analysis

Art Unit 1699's allowance rate of 75.2% places it in the 41% percentile among all USPTO art units. This art unit has a below-average allowance rate compared to other art units.

Prosecution Patterns

Applications in Art Unit 1699 receive an average of 1.89 office actions before reaching final disposition (in the 56% percentile). The median prosecution time is 30 months (in the 41% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.